0<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279768/" target="_blank">Article ID: PMC7279768 <h1 class="content-title">RECURRENT PAINFUL HASHIMOTO THYROIDITIS SUCCESSFULLY TREATED BY THYROIDECTOMY</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279768/bin/i2376-0605-6-1-e9-f01.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279768/bin/i2376-0605-6-1-e9-f01.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p16">Ultrasound of the thyroid gland showing both the left (A) and right (B) lobes. Bilateral lobes showed heterogeneous echogenicity. There was no evidence of discrete nodules.</p></div></div></div><hr>1<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279768/" target="_blank">Article ID: PMC7279768 <h1 class="content-title">RECURRENT PAINFUL HASHIMOTO THYROIDITIS SUCCESSFULLY TREATED BY THYROIDECTOMY</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279768/bin/i2376-0605-6-1-e9-f02.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279768/bin/i2376-0605-6-1-e9-f02.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p19">Histopathology of the thyroid gland under hematoxylin and eosin stain (A and B) and IgG4 immunohistochemical stain (C and D). Low-power view of the Hashimoto thyroiditis with its recognizable germinal centers and low-to-moderate levels of fibrosis (A). High-power view of a group of germinal centers with entrapped thyroid follicles and marked lymphocytic and plasmacytic infiltrate (B). Panels C and D show the same area stained with IgG4 immunohistochemistry, revealing many interspersed IgG4-positive plasma cells (up to 50 per high-power field).</p></div></div></div><hr>0<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279771/" target="_blank">Article ID: PMC7279771 <h1 class="content-title">THERAPEUTIC PLASMA EXCHANGE AS A BRIDGE TO TOTAL THYROIDECTOMY IN PATIENTS WITH SEVERE THYROTOXICOSIS</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279771/bin/i2376-0605-6-1-e14-f01.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279771/bin/i2376-0605-6-1-e14-f01.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p16">Measured free T4 levels during TPE treatment. T4 = thyroxine; TPE = therapeutic plasma exchange.</p></div></div></div><hr>0<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279774/" target="_blank">Article ID: PMC7279774 <h1 class="content-title">HYPOTHYROIDISM AND GOITER IN A YOUNG MALE WITH SUSPECTED DIETARY IODINE DEFICIENCY FOLLOWED BY THYROTOXICOSIS AFTER IODINE SUPPLEMENTATION</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279774/bin/i2376-0605-6-1-e19-f01.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279774/bin/i2376-0605-6-1-e19-f01.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p11">Ultrasound of the thyroid gland showing enlarged left lobe measuring about 7.4 cm at its widest.</p></div></div></div><hr>1<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279774/" target="_blank">Article ID: PMC7279774 <h1 class="content-title">HYPOTHYROIDISM AND GOITER IN A YOUNG MALE WITH SUSPECTED DIETARY IODINE DEFICIENCY FOLLOWED BY THYROTOXICOSIS AFTER IODINE SUPPLEMENTATION</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279774/bin/i2376-0605-6-1-e19-f02.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279774/bin/i2376-0605-6-1-e19-f02.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p13">Radioactive iodine uptake scan of the thyroid gland showing diffusely increased uptake of iodine at 91% over 24 hours.</p></div></div></div><hr>0<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279773/" target="_blank">Article ID: PMC7279773 <h1 class="content-title">SPONTANEOUS RESOLUTION OF PRIMARY HYPERCORTISOLISM OF CUSHING DISEASE AFTER PITUITARY HEMORRHAGE</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279773/bin/i2376-0605-6-1-e23-f01.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279773/bin/i2376-0605-6-1-e23-f01.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p12">MRI of the pituitary at the time of initial presentation showing an indeterminate sellar/suprasellar heterogeneous mass measuring up to 2 cm (shown by arrows). A, Coronal section without contrast. B, Sagittal section without contrast. C, Coronal section with contrast demonstrating lack of enhancement. D, Sagittal section with contrast demonstrating lack of enhancement. There is extension to the optic chiasm. Original differential diagnosis per neuroradiology included an atypical pituitary macroadenoma, less likely craniopharyngioma, germ cell tumor, or metastasis. MRI = magnetic resonance imaging.</p></div></div></div><hr>1<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279773/" target="_blank">Article ID: PMC7279773 <h1 class="content-title">SPONTANEOUS RESOLUTION OF PRIMARY HYPERCORTISOLISM OF CUSHING DISEASE AFTER PITUITARY HEMORRHAGE</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279773/bin/i2376-0605-6-1-e23-f02.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279773/bin/i2376-0605-6-1-e23-f02.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p18">Follow-up MRI with contrast of the pituitary showing an interval decrease in the size of the pituitary lesion, retrospectively suggestive of interval resorption of a hemorrhage secondary to an underlying adenoma. A and B, At 2 months. C and D, At 4 months. Hypoenhancing region below the gland is noted, scalloping the sphenoid bone suggestive of a residual adenoma, measuring approximately 8 mm in diameter. There is no residual suprasellar extension or mass effect on the optic chiasm. E and F, Most recent MRI with contrast at 12 months, showing an overall continued mild improvement in the size of the pituitary gland with a slight concavity of its superior surface. Additionally noted was a minimally improved 6 mm focus of delayed enhancement within the pituitary gland, reflecting a residual microadenoma. MRI = magnetic resonance imaging.</p></div></div></div><hr>0<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279775/" target="_blank">Article ID: PMC7279775 <h1 class="content-title">NOVEL <em>XRCC4</em> MUTATIONS IN AN INFANT WITH MICROCEPHALIC PRIMORDIAL DWARFISM, DILATED CARDIOMYOPATHY, SUBCLINICAL HYPOTHYROIDISM, AND EARLY DEATH: EXPANDING THE PHENOTYPE OF <em>XRCC4</em> MUTATIONS</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279775/bin/i2376-0605-6-1-e1-f01.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279775/bin/i2376-0605-6-1-e1-f01.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p18">Left atrial and ventricular dilation on echocardiogram at 2 months of life.</p></div></div></div><hr>0<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279778/" target="_blank">Article ID: PMC7279778 <h1 class="content-title">THE NOVEL USE OF STEREOTACTIC RADIOTHERAPY FOR REMNANT ADRENAL TISSUE IN NELSON SYNDROME</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279778/bin/i2376-0605-6-1-e33-f01.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279778/bin/i2376-0605-6-1-e33-f01.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p13">Adrenal radiation planning depicted on computed tomography scan of the abdomen. A, Planned target volume (in red) for adrenal SBRT included a 0.5 cm safety margin around the radiologic abnormality (in green). Organs at risk for damage from radiation treatment (OARs) included bilateral kidneys (purple), spinal cord (turquoise), stomach (magenta), bowel (blue), and liver (yellow). B, Image shows orientation of stereotactic radiotherapy beam arcs. One clockwise and one counterclockwise partial-arc arrangement was utilized to treat each target. C, The adrenal beds were treated to 3,900 cGy in 3 fractions. Dose color-wash at approximately 50% level shows rapid dose fall-off and excellent sparing of OARs. SBRT = stereotactic body radiotherapy.</p></div></div></div><hr>1<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279778/" target="_blank">Article ID: PMC7279778 <h1 class="content-title">THE NOVEL USE OF STEREOTACTIC RADIOTHERAPY FOR REMNANT ADRENAL TISSUE IN NELSON SYNDROME</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279778/bin/i2376-0605-6-1-e33-f02.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279778/bin/i2376-0605-6-1-e33-f02.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p14">Graph shows changes in serum cortisol and plasma ACTH levels over time. Treatment chronology included for reference. ACTH = adrenocortico-tropic hormone; SBRT = stereotactic body radiotherapy.</p></div></div></div><hr>0<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279770/" target="_blank">Article ID: PMC7279770 <h1 class="content-title">MANIFESTATIONS OF GLUCAGONOMA SYNDROME</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279770/bin/i2376-0605-6-1-e46-f01.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279770/bin/i2376-0605-6-1-e46-f01.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p10">Migratory necrolytic erythema on the face showing hyperpigmented and erythematous lesions.</p></div></div></div><hr>1<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279770/" target="_blank">Article ID: PMC7279770 <h1 class="content-title">MANIFESTATIONS OF GLUCAGONOMA SYNDROME</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279770/bin/i2376-0605-6-1-e46-f02.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279770/bin/i2376-0605-6-1-e46-f02.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p11">Cheilitis and glossitis.</p></div></div></div><hr>2<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279770/" target="_blank">Article ID: PMC7279770 <h1 class="content-title">MANIFESTATIONS OF GLUCAGONOMA SYNDROME</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279770/bin/i2376-0605-6-1-e46-f03.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279770/bin/i2376-0605-6-1-e46-f03.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p13">Axial computed tomography of the abdomen showing masses in the pancreatic tail and right hepatic lobe.</p></div></div></div><hr>3<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279770/" target="_blank">Article ID: PMC7279770 <h1 class="content-title">MANIFESTATIONS OF GLUCAGONOMA SYNDROME</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279770/bin/i2376-0605-6-1-e46-f04.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279770/bin/i2376-0605-6-1-e46-f04.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p16">Histology (×40) showing nodular and trabecular structures formed by cells with broad, granular eosinophilic cytoplasm and homogeneous nuclei. Slight pleomorphism and some visible nucleoli are also observed, but no important mitotic activity is observed.</p></div></div></div><hr>0<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279776/" target="_blank">Article ID: PMC7279776 <h1 class="content-title">A CASE OF ACQUIRED GENERALIZED LIPODYSTROPHY ASSOCIATED WITH PEMBROLIZUMAB IN A PATIENT WITH METASTATIC MALIGNANT MELANOMA</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279776/bin/i2376-0605-6-1-e40-f01.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279776/bin/i2376-0605-6-1-e40-f01.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p15">Clinical features of pembrolizumab-induced lipodystrophy. Clinical photographs that demonstrate the change of fat distribution before and after treatment with pembrolizumab. A, Before treatment. B, After initiation of immunotherapy. There is central obesity and decreased adipose tissue in the extremities.</p></div></div></div><hr>1<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279776/" target="_blank">Article ID: PMC7279776 <h1 class="content-title">A CASE OF ACQUIRED GENERALIZED LIPODYSTROPHY ASSOCIATED WITH PEMBROLIZUMAB IN A PATIENT WITH METASTATIC MALIGNANT MELANOMA</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279776/bin/i2376-0605-6-1-e40-f02.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279776/bin/i2376-0605-6-1-e40-f02.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p17">Changes in weight, triglyceride levels, and insulin requirements over time. A, Changes in triglyceride level and weight. B, Changes in triglyceride level and insulin requirements.</p></div></div></div><hr>2<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279776/" target="_blank">Article ID: PMC7279776 <h1 class="content-title">A CASE OF ACQUIRED GENERALIZED LIPODYSTROPHY ASSOCIATED WITH PEMBROLIZUMAB IN A PATIENT WITH METASTATIC MALIGNANT MELANOMA</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279776/bin/i2376-0605-6-1-e40-f03.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279776/bin/i2376-0605-6-1-e40-f03.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p28">Graphic representation of the diagnostic workup of acute generalized lipodystrophy in patients treated with PD-1 therapy. Abs = antibodies; AGL = acquired generalized lipodystrophy; ANA = antinuclear antibody; anti-dsDNA = anti-double stranded deoxyribonucleic acid antibody; CT = computed tomography; FBG = fast blood glucose; HIV = human immunodeficiency virus; PD-1 = antiprogrammed cell death receptor-1; SPEP = serum protein electrophoresis; TG = triglyceride; US = ultrasound.</p></div></div></div><hr>0<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279775/" target="_blank">Article ID: PMC7279775 <h1 class="content-title">NOVEL <em>XRCC4</em> MUTATIONS IN AN INFANT WITH MICROCEPHALIC PRIMORDIAL DWARFISM, DILATED CARDIOMYOPATHY, SUBCLINICAL HYPOTHYROIDISM, AND EARLY DEATH: EXPANDING THE PHENOTYPE OF <em>XRCC4</em> MUTATIONS</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279775/bin/i2376-0605-6-1-e1-f01.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279775/bin/i2376-0605-6-1-e1-f01.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p18">Left atrial and ventricular dilation on echocardiogram at 2 months of life.</p></div></div></div><hr>0<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279774/" target="_blank">Article ID: PMC7279774 <h1 class="content-title">HYPOTHYROIDISM AND GOITER IN A YOUNG MALE WITH SUSPECTED DIETARY IODINE DEFICIENCY FOLLOWED BY THYROTOXICOSIS AFTER IODINE SUPPLEMENTATION</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279774/bin/i2376-0605-6-1-e19-f01.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279774/bin/i2376-0605-6-1-e19-f01.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p11">Ultrasound of the thyroid gland showing enlarged left lobe measuring about 7.4 cm at its widest.</p></div></div></div><hr>1<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279774/" target="_blank">Article ID: PMC7279774 <h1 class="content-title">HYPOTHYROIDISM AND GOITER IN A YOUNG MALE WITH SUSPECTED DIETARY IODINE DEFICIENCY FOLLOWED BY THYROTOXICOSIS AFTER IODINE SUPPLEMENTATION</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279774/bin/i2376-0605-6-1-e19-f02.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279774/bin/i2376-0605-6-1-e19-f02.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p13">Radioactive iodine uptake scan of the thyroid gland showing diffusely increased uptake of iodine at 91% over 24 hours.</p></div></div></div><hr>0<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279768/" target="_blank">Article ID: PMC7279768 <h1 class="content-title">RECURRENT PAINFUL HASHIMOTO THYROIDITIS SUCCESSFULLY TREATED BY THYROIDECTOMY</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279768/bin/i2376-0605-6-1-e9-f01.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279768/bin/i2376-0605-6-1-e9-f01.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p16">Ultrasound of the thyroid gland showing both the left (A) and right (B) lobes. Bilateral lobes showed heterogeneous echogenicity. There was no evidence of discrete nodules.</p></div></div></div><hr>1<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279768/" target="_blank">Article ID: PMC7279768 <h1 class="content-title">RECURRENT PAINFUL HASHIMOTO THYROIDITIS SUCCESSFULLY TREATED BY THYROIDECTOMY</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279768/bin/i2376-0605-6-1-e9-f02.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279768/bin/i2376-0605-6-1-e9-f02.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p19">Histopathology of the thyroid gland under hematoxylin and eosin stain (A and B) and IgG4 immunohistochemical stain (C and D). Low-power view of the Hashimoto thyroiditis with its recognizable germinal centers and low-to-moderate levels of fibrosis (A). High-power view of a group of germinal centers with entrapped thyroid follicles and marked lymphocytic and plasmacytic infiltrate (B). Panels C and D show the same area stained with IgG4 immunohistochemistry, revealing many interspersed IgG4-positive plasma cells (up to 50 per high-power field).</p></div></div></div><hr>0<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279771/" target="_blank">Article ID: PMC7279771 <h1 class="content-title">THERAPEUTIC PLASMA EXCHANGE AS A BRIDGE TO TOTAL THYROIDECTOMY IN PATIENTS WITH SEVERE THYROTOXICOSIS</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279771/bin/i2376-0605-6-1-e14-f01.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279771/bin/i2376-0605-6-1-e14-f01.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p16">Measured free T4 levels during TPE treatment. T4 = thyroxine; TPE = therapeutic plasma exchange.</p></div></div></div><hr>0<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279773/" target="_blank">Article ID: PMC7279773 <h1 class="content-title">SPONTANEOUS RESOLUTION OF PRIMARY HYPERCORTISOLISM OF CUSHING DISEASE AFTER PITUITARY HEMORRHAGE</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279773/bin/i2376-0605-6-1-e23-f01.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279773/bin/i2376-0605-6-1-e23-f01.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p12">MRI of the pituitary at the time of initial presentation showing an indeterminate sellar/suprasellar heterogeneous mass measuring up to 2 cm (shown by arrows). A, Coronal section without contrast. B, Sagittal section without contrast. C, Coronal section with contrast demonstrating lack of enhancement. D, Sagittal section with contrast demonstrating lack of enhancement. There is extension to the optic chiasm. Original differential diagnosis per neuroradiology included an atypical pituitary macroadenoma, less likely craniopharyngioma, germ cell tumor, or metastasis. MRI = magnetic resonance imaging.</p></div></div></div><hr>1<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279773/" target="_blank">Article ID: PMC7279773 <h1 class="content-title">SPONTANEOUS RESOLUTION OF PRIMARY HYPERCORTISOLISM OF CUSHING DISEASE AFTER PITUITARY HEMORRHAGE</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279773/bin/i2376-0605-6-1-e23-f02.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279773/bin/i2376-0605-6-1-e23-f02.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p18">Follow-up MRI with contrast of the pituitary showing an interval decrease in the size of the pituitary lesion, retrospectively suggestive of interval resorption of a hemorrhage secondary to an underlying adenoma. A and B, At 2 months. C and D, At 4 months. Hypoenhancing region below the gland is noted, scalloping the sphenoid bone suggestive of a residual adenoma, measuring approximately 8 mm in diameter. There is no residual suprasellar extension or mass effect on the optic chiasm. E and F, Most recent MRI with contrast at 12 months, showing an overall continued mild improvement in the size of the pituitary gland with a slight concavity of its superior surface. Additionally noted was a minimally improved 6 mm focus of delayed enhancement within the pituitary gland, reflecting a residual microadenoma. MRI = magnetic resonance imaging.</p></div></div></div><hr>0<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279778/" target="_blank">Article ID: PMC7279778 <h1 class="content-title">THE NOVEL USE OF STEREOTACTIC RADIOTHERAPY FOR REMNANT ADRENAL TISSUE IN NELSON SYNDROME</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279778/bin/i2376-0605-6-1-e33-f01.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279778/bin/i2376-0605-6-1-e33-f01.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p13">Adrenal radiation planning depicted on computed tomography scan of the abdomen. A, Planned target volume (in red) for adrenal SBRT included a 0.5 cm safety margin around the radiologic abnormality (in green). Organs at risk for damage from radiation treatment (OARs) included bilateral kidneys (purple), spinal cord (turquoise), stomach (magenta), bowel (blue), and liver (yellow). B, Image shows orientation of stereotactic radiotherapy beam arcs. One clockwise and one counterclockwise partial-arc arrangement was utilized to treat each target. C, The adrenal beds were treated to 3,900 cGy in 3 fractions. Dose color-wash at approximately 50% level shows rapid dose fall-off and excellent sparing of OARs. SBRT = stereotactic body radiotherapy.</p></div></div></div><hr>1<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279778/" target="_blank">Article ID: PMC7279778 <h1 class="content-title">THE NOVEL USE OF STEREOTACTIC RADIOTHERAPY FOR REMNANT ADRENAL TISSUE IN NELSON SYNDROME</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279778/bin/i2376-0605-6-1-e33-f02.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279778/bin/i2376-0605-6-1-e33-f02.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p14">Graph shows changes in serum cortisol and plasma ACTH levels over time. Treatment chronology included for reference. ACTH = adrenocortico-tropic hormone; SBRT = stereotactic body radiotherapy.</p></div></div></div><hr>0<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279776/" target="_blank">Article ID: PMC7279776 <h1 class="content-title">A CASE OF ACQUIRED GENERALIZED LIPODYSTROPHY ASSOCIATED WITH PEMBROLIZUMAB IN A PATIENT WITH METASTATIC MALIGNANT MELANOMA</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279776/bin/i2376-0605-6-1-e40-f01.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279776/bin/i2376-0605-6-1-e40-f01.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p15">Clinical features of pembrolizumab-induced lipodystrophy. Clinical photographs that demonstrate the change of fat distribution before and after treatment with pembrolizumab. A, Before treatment. B, After initiation of immunotherapy. There is central obesity and decreased adipose tissue in the extremities.</p></div></div></div><hr>1<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279776/" target="_blank">Article ID: PMC7279776 <h1 class="content-title">A CASE OF ACQUIRED GENERALIZED LIPODYSTROPHY ASSOCIATED WITH PEMBROLIZUMAB IN A PATIENT WITH METASTATIC MALIGNANT MELANOMA</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279776/bin/i2376-0605-6-1-e40-f02.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279776/bin/i2376-0605-6-1-e40-f02.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p17">Changes in weight, triglyceride levels, and insulin requirements over time. A, Changes in triglyceride level and weight. B, Changes in triglyceride level and insulin requirements.</p></div></div></div><hr>2<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279776/" target="_blank">Article ID: PMC7279776 <h1 class="content-title">A CASE OF ACQUIRED GENERALIZED LIPODYSTROPHY ASSOCIATED WITH PEMBROLIZUMAB IN A PATIENT WITH METASTATIC MALIGNANT MELANOMA</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279776/bin/i2376-0605-6-1-e40-f03.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279776/bin/i2376-0605-6-1-e40-f03.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p28">Graphic representation of the diagnostic workup of acute generalized lipodystrophy in patients treated with PD-1 therapy. Abs = antibodies; AGL = acquired generalized lipodystrophy; ANA = antinuclear antibody; anti-dsDNA = anti-double stranded deoxyribonucleic acid antibody; CT = computed tomography; FBG = fast blood glucose; HIV = human immunodeficiency virus; PD-1 = antiprogrammed cell death receptor-1; SPEP = serum protein electrophoresis; TG = triglyceride; US = ultrasound.</p></div></div></div><hr>0<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279770/" target="_blank">Article ID: PMC7279770 <h1 class="content-title">MANIFESTATIONS OF GLUCAGONOMA SYNDROME</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279770/bin/i2376-0605-6-1-e46-f01.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279770/bin/i2376-0605-6-1-e46-f01.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p10">Migratory necrolytic erythema on the face showing hyperpigmented and erythematous lesions.</p></div></div></div><hr>1<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279770/" target="_blank">Article ID: PMC7279770 <h1 class="content-title">MANIFESTATIONS OF GLUCAGONOMA SYNDROME</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279770/bin/i2376-0605-6-1-e46-f02.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279770/bin/i2376-0605-6-1-e46-f02.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p11">Cheilitis and glossitis.</p></div></div></div><hr>2<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279770/" target="_blank">Article ID: PMC7279770 <h1 class="content-title">MANIFESTATIONS OF GLUCAGONOMA SYNDROME</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279770/bin/i2376-0605-6-1-e46-f03.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279770/bin/i2376-0605-6-1-e46-f03.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p13">Axial computed tomography of the abdomen showing masses in the pancreatic tail and right hepatic lobe.</p></div></div></div><hr>3<div style="font-size: 50%;" ><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279770/" target="_blank">Article ID: PMC7279770 <h1 class="content-title">MANIFESTATIONS OF GLUCAGONOMA SYNDROME</h1></a><div class="fig"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279770/bin/i2376-0605-6-1-e46-f04.jpg" target="_blank"> 
                <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279770/bin/i2376-0605-6-1-e46-f04.jpg" style="width: 45%; height: 45%;" />
                <a/><div class="caption"><p id="__p16">Histology (×40) showing nodular and trabecular structures formed by cells with broad, granular eosinophilic cytoplasm and homogeneous nuclei. Slight pleomorphism and some visible nucleoli are also observed, but no important mitotic activity is observed.</p></div></div></div><hr>